The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

While the Dutch company expects to report profits up between 4% and 8% when it releases its full-year 2024 financial results ...

Ozempic and Wegovy have been added to Medicare's list of drugs, whose prices will be negotiated between drug makers and the government.

Concern is growing among Democrats after President Donald Trump reversed some of the former president’s executive orders, including efforts to reduce prescription drug costs for Medicare and ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...